{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T03:19:32Z","timestamp":1791861572774,"version":"4.3.4"},"reference-count":26,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme United Kingdom","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.urolonc.2025.12.018","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T10:22:56Z","timestamp":1768386176000},"page":"110982","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Real-world treatment patterns, recurrence, and overall survival of patients with muscle-invasive bladder cancer undergoing radical cystectomy in U.S. oncology practice"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-6819-5764","authenticated-orcid":false,"given":"Patrick","family":"Squires","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Coutinho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon G.","family":"Tepsick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aljosja","family":"Rogiers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chethan","family":"Ramamurthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haojie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd M.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2025.12.018_bib0001","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urolonc.2025.12.018_bib0002","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2025.12.018_bib0003","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211047352","article-title":"Metastatic urothelial cancer: a rapidly changing treatment landscape","volume":"13","author":"Stecca","year":"2021","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.urolonc.2025.12.018_bib0004","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.12.018_bib0005","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00345-015-1729-7","article-title":"Open radical cystectomy: still the gold standard for muscle invasive bladder cancer","volume":"34","author":"Kiss","year":"2016","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2025.12.018_bib0006","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1159\/000075962","article-title":"Survival rates after radical cystectomy according to tumor stage of bladder carcinoma at first presentation","volume":"72","author":"May","year":"2004","journal-title":"Urol Int"},{"key":"10.1016\/j.urolonc.2025.12.018_bib0007","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1471-2318-12-18","article-title":"Radical cystectomy over the age of 75 is safe and increases survival","volume":"12","author":"Tyritzis","year":"2012","journal-title":"BMC Geriatr"},{"key":"10.1016\/j.urolonc.2025.12.018_bib0008","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa2401497","article-title":"Standard or extended lymphadenectomy for muscle-invasive bladder cancer","volume":"391","author":"Lerner","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2025.12.018_bib0009","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1007\/s11255-022-03339-6","article-title":"Survival outcomes of patients with muscle-invasive bladder cancer according to pathological response at radical cystectomy with or without neo-adjuvant chemotherapy: a case-control matching study","volume":"54","author":"van Ginkel","year":"2022","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.urolonc.2025.12.018_bib0010","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1007\/s00432-021-03582-x","article-title":"Comparison of clinical outcomes in patients with localized or locally advanced urothelial carcinoma treated with neoadjuvant chemotherapy involving gemcitabine-cisplatin and high dose-intensity MVAC","volume":"147","author":"Lee","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.urolonc.2025.12.018_bib0011","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/JCO.21.02051","article-title":"Dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin or gemcitabine and cisplatin as perioperative chemotherapy for patients with nonmetastatic muscle-invasive bladder cancer: results of the GETUG-AFU V05 VESPER trial","volume":"40","author":"Pfister","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2025.12.018_bib0012","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer","volume":"391","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2025.12.018_bib0013","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/JU.0000000000003981","article-title":"Treatment of non-metastatic muscle-invasive bladder cancer: AUA\/ASCO\/SUO guideline (2017; Amended 2020, 2024)","volume":"212","author":"Holzbeierlein","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2025.12.018_bib0014","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.eururo.2005.04.006","article-title":"Advanced bladder cancer meta-analysis C. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration","volume":"48","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.12.018_bib0015","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1634\/theoncologist.2015-0440","article-title":"Neoadjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and two-step meta-analysis","volume":"21","author":"Yin","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.urolonc.2025.12.018_bib0016","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.eururo.2014.09.007","article-title":"Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer","volume":"67","author":"Zargar","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.12.018_bib0017","first-page":"24","article-title":"Trends and disparities in the use of neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma","volume":"13","author":"Duplisea","year":"2019","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.urolonc.2025.12.018_bib0018","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/cncr.25429","article-title":"Contemporary use of perioperative cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer","volume":"117","author":"Raj","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2025.12.018_bib0019","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/UPJ.0000000000000200","article-title":"Understanding the barriers to neoadjuvant chemotherapy in patients with muscle invasive bladder cancer: a quality improvement initiative","volume":"8","author":"Andino","year":"2021","journal-title":"Urol Pract"},{"key":"10.1016\/j.urolonc.2025.12.018_bib0020","doi-asserted-by":"crossref","first-page":"E17","DOI":"10.1111\/bju.12274","article-title":"Eligibility for neoadjuvant\/adjuvant cisplatin-based chemotherapy among radical cystectomy patients","volume":"113","author":"Thompson","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2025.12.018_bib0021","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41585-020-00404-6","article-title":"Defining cisplatin eligibility in patients with muscle-invasive bladder cancer","volume":"18","author":"Jiang","year":"2021","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.urolonc.2025.12.018_bib0022","doi-asserted-by":"crossref","first-page":"S576","DOI":"10.1016\/j.jval.2024.10.3581","article-title":"RWD23 Addition of open administrative claims significantly improves capture of mortality in electronic health record (EHR)-focused real-world data (RWD)","volume":"27","author":"Slipski","year":"2024","journal-title":"Value in Health"},{"key":"10.1016\/j.urolonc.2025.12.018_bib0023","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s12874-025-02603-4","article-title":"Behavior of test specificity under an imperfect gold standard: findings from a simulation study and analysis of real-world oncology data","volume":"25","author":"Walker","year":"2025","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.urolonc.2025.12.018_bib0024","article-title":"Improving real-world mortality data quality in oncology research: augmenting electronic medical records with obituary, Social Security death index, and commercial claims data","volume":"7","author":"Shao","year":"2023","journal-title":"JCO Clin Cancer Inform"},{"key":"10.1016\/j.urolonc.2025.12.018_bib0025","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00345-017-2115-4","article-title":"Patterns and predictors of recurrence after open radical cystectomy for bladder cancer: a comprehensive review of the literature","volume":"36","author":"Mari","year":"2018","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2025.12.018_bib0026","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.eururo.2013.06.049","article-title":"Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta-analysis","volume":"65","author":"Petrelli","year":"2014","journal-title":"Eur Urol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925005010?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925005010?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T23:58:26Z","timestamp":1773964706000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143925005010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1078143925005010"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.12.018","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world treatment patterns, recurrence, and overall survival of patients with muscle-invasive bladder cancer undergoing radical cystectomy in U.S. oncology practice","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.12.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s) and Merck & Co., Inc., Rahway, NJ, USA and its affiliates. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"110982"}}